H3R antagonists ABT-288, GSK-239512, and MK0249 have recently completed Phase II trials for cognitive impairments in schizophrenia (NCT-ID NCT01077700, NCT01009060, and NCT00506077) although the outcomes of these studies remain undisclosed so far. Here, HRH3 is linked to Cognitive impairment.